Spn Mouse shRNA Plasmid (Locus ID 20737)

CAT#: TL502133

Spn - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided



Need custom shRNA service?
Get a free quote

CNY 7,740.00


货期*
2周

规格
    • 1 kit

Product images

经常一起买 (3)
Lenti-vpak packaging kit - packaging plasmids and transfection reagent
    • 10 reactions

CNY 5,420.00


TurboFectin Transfection Reagent (1 mL in 1 vial)
    • 1 ml in 1 vial

CNY 4,090.00


Lateral flow testing sticks used for the semi-quantitative detection of the lentiviral p24 protein, 20 tests
    • 20 Tests

CNY 4,070.00

Specifications

Product Data
Product Name Spn Mouse shRNA Plasmid (Locus ID 20737)
Locus ID 20737
UniProt ID P15702
Synonyms A630014B01Rik; Cd43; Galgp; Ly-48; Ly48
Vector pGFP-C-shLenti
Format Lentiviral plasmids
Kit Components Spn - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 20737). 5µg purified plasmid DNA per construct
29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq BC100738, BC100739, BC100740, BC100741, NM_001037810, NM_009259, NR_110337, NM_001037810.1, NM_001037810.2, NM_009259.1, NM_009259.2, NM_009259.3, NM_009259.4, NM_009259.5
Summary Predominant cell surface sialoprotein of leukocytes which regulates multiple T-cell functions, including T-cell activation, proliferation, differentiation, trafficking and migration. Positively regulates T-cell trafficking to lymph-nodes via its association with ERM proteins (EZR, RDX and MSN) (PubMed:17638845, PubMed:21289089, PubMed:11728336). Negatively regulates Th2 cell differentiation and predisposes the differentiation of T-cells towards a Th1 lineage commitment (PubMed:18490738). Promotes the expression of IFN-gamma by T-cells during T-cell receptor (TCR) activation of naive cells and induces the expression of IFN-gamma by CD4(+) T-cells and to a lesser extent by CD8(+) T-cells. Plays a role in preparing T-cells for cytokine sensing and differentiation into effector cells by inducing the expression of cytokine receptors IFNGR and IL4R, promoting IFNGR and IL4R signaling and by mediating the clustering of IFNGR with TCR (By similarity). Acts as a major E-selectin ligand responsible for Th17 cell rolling on activated vasculature and recruitment during inflammation. Mediates Th17 cells, but not Th1 cells, adhesion to E-selectin (PubMed:26700769). Acts as a T-cell counter-receptor for SIGLEC1 (PubMed:11238599).[UniProtKB/Swiss-Prot Function]
shRNA Design These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...